Human clinical trials of a potential Covid-19 vaccine have begun by the University of Queensland in Australia. Pre-clinical tests showed that the vaccine, developed by University of Queensland, induced antibodies capable of neutralising the virus. During phase I of the clinical trial, 120 healthy volunteers, aged between 18 to 55, will be administered a shot while some will be given a placebo. They will be injected with two doses every four weeks, according to reports. Preliminary data is likely to be available in three months and if successful, a larger trial with a wide population will be conducted. For the trial, the vaccine candidate was produced by CSIRO’s advanced biologics production facility in Melbourne.